Akriderm 0.05% ointment for external use 30 g

Indications

Skin diseases responsive to glucocorticosteroid therapy:
? atopic dermatitis;
? allergic contact dermatitis;
? eczema (various forms);
? contact dermatitis (including occupational) and other non-allergic dermatoses (including solar and radiation dermatitis);
? reactions to insect bites;
? psoriasis;
? bullous dermatoses;
? discoid lupus erythematosus;
? lichen planus;
? exudative multiforme erythema;
? pruritus of various etiology.

Method of Application and Dosage

For external use. Akriderm ointment is applied in a thin layer to the affected area of the skin 2 times a day - in the morning and in the evening, gently rubbing it in. On areas with thicker skin (for example, elbows, palms, and soles), as well as places where the medication is easily wiped off, Akriderm ointment can be applied more frequently. The duration of treatment depends on the effectiveness and tolerability of therapy and usually does not exceed 4 weeks. Within a year, repeated courses of therapy may be possible.

If clinical improvement does not occur, it is necessary to clarify the diagnosis.

In children and patients with facial skin lesions, the treatment course should not exceed 5 days.

Side Effects

As a rule, they are mild. When using topical glucocorticosteroids, the following may occur: skin itching, burning, irritation, dryness, folliculitis, hypertrichosis, striae, acne-like rashes ("steroid" acne), hypopigmentation, perioral dermatitis, allergic contact dermatitis. With prolonged use, as well as the use of occlusive dressings - skin maceration, secondary infection, skin atrophy, local hirsutism, telangiectasia, heat rash, purpura.

When applied to large areas of the body, especially in children, systemic side effects of glucocorticosteroids may occur (hyperglycemia, glucosuria, reversible suppression of adrenal cortex function, manifestation of Cushing's syndrome).

If side effects not described in the instructions occur, consult a doctor.

Overdose

Section: Composition

100 g of the ointment contains:
active ingredient: betamethasone dipropionate (micronized betamethasone dipropionate) calculated as 100% substance - 0.064 g, which is equivalent to 0.05 g of betamethasone;
excipients: propylparaben, liquid paraffin (vaseline oil), isopropyl myristate, vaseline.

Description of the dosage form

Translucent ointment from white to white with a yellowish tint.

Contraindications

Increased sensitivity to betamethasone or other components of the drug.
Tuberculosis of the skin, skin manifestations of syphilis, bacterial, fungal, viral (chickenpox, herpes simplex) skin diseases, post-vaccination skin reactions, open wounds, trophic ulcers of the lower leg, rosacea, vulgar acne, skin cancer, nevus, atheroma, melanoma, hemangioma, xanthoma, sarcoma, lactation period, and children under 1 year of age.
With caution
With prolonged use or application to large areas: cataract, diabetes mellitus, glaucoma, tuberculosis.
Use during pregnancy and lactation
The safety of topical glucocorticoids in pregnant women has not been established; the prescription of drugs in this group during pregnancy is justified only if the potential benefit to the mother outweighs the possible risk to the fetus. During pregnancy, drugs in this group should not be used in high doses or for extended periods.
If the drug needs to be used during lactation, it is recommended to discontinue breastfeeding.

Section: Special Instructions

It is not recommended to use the drug externally on the facial skin for an extended period, as it may lead to the development of rosacea, perioral dermatitis, and acne. The treatment course should not exceed 5 days.
Akriderm ointment is not intended for use in ophthalmology. Avoid contact with the eyes. If the drug comes into contact with the mucous membranes of the eyes, cataracts, glaucoma, fungal eye infections, and exacerbation of herpes infection may develop.
With prolonged treatment, when applying the drug to large areas of skin, as well as in the armpits and groin folds, and when using occlusive dressings or diapers, systemic absorption of glucocorticosteroids may occur.
For children from 1 year old, the drug is prescribed only for strict indications and under medical supervision, as there is a possibility of developing systemic side effects associated with betamethasone.
When using the drug on large surfaces and/or under an occlusive dressing, suppression of the hypothalamic-pituitary-adrenal system function and the development of hypercortisolism symptoms may occur, with a decrease in growth hormone excretion and an increase in intracranial pressure.
When using the ointment in children aged 1 year and older, it is necessary to limit the overall duration of treatment and exclude activities that lead to increased absorption and resorption (warming, fixing, and occlusive dressings, diapers).
Effect on the ability to drive vehicles and operate machinery
No effect.

Side effects

When applied to large areas of the body, especially in children, systemic side effects of corticosteroids may occur (hyperglycemia, glucosuria, reversible suppression of adrenal cortex function, manifestation of Cushing's syndrome).

Section: Overdose

Acute overdose is unlikely; however, with excessive or prolonged use of the drug, chronic overdose may occur, accompanied by signs of hypercorticism: hyperglycemia, glucosuria, reversible suppression of adrenal cortex function, manifestation of Cushing's syndrome. Treatment: gradual withdrawal of the drug is recommended, and symptomatic treatment should be provided if necessary.

Interaction

The drug has not shown interactions with other medications.
Special instructions

Pharmacodynamics

Akriderm is a glucocorticosteroid for external use. It has anti-inflammatory, anti-allergic, anti-exudative, vasoconstrictive, anti-itch, and antiproliferative effects. It inhibits the accumulation of leukocytes, the release of lysosomal enzymes, and pro-inflammatory mediators at the site of inflammation, suppresses phagocytosis, reduces vascular-tissue permeability, and prevents the formation of inflammatory edema. When applied to the skin surface, the drug exerts a rapid and strong effect at the site of inflammation, reducing the severity of objective symptoms (erythema, edema, lichenification) and subjective sensations (itching, irritation, pain).

Section: Pharmacokinetics

When the drug is applied topically in therapeutic doses, the transdermal absorption of the active substance into the bloodstream is very minimal. The use of occlusive dressings, inflammation, and skin diseases increases the transdermal absorption of betamethasone, which may lead to an increased risk of systemic side effects.

Description

Akriderm ointment for external use 0.05% is an anti-inflammatory and anti-allergic medication for external use. It contains the active ingredient - betamethasone dipropionate, which has a powerful anti-allergic and anti-inflammatory effect. The ointment is used for various skin conditions, such as eczema, psoriasis, dermatitis, atopic dermatitis, and others. It reduces itching, inflammation, and redness of the skin, promotes the healing of wounds and ulcers, and alleviates swelling.

In addition, Akriderm ointment can be used to treat skin hyperpigmentation, including that following burns, as well as for itching and irritation caused by insects and other allergens. The use of the ointment should be agreed upon with the attending physician.